INTERNATIONAL PATENT: WAVERLEY PHARMA INC. FILES APPLICATION FOR "SUBSTITUTED (3-HYDROQUINAZOLIN-4-ONE) DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USE AS POTENT & SELECTIVE POLY [ADP RIBOSE] POLYMERASE 1(P ARP-1) INHIBITORS FOR THE TREATMENT OF CANCER"

GENEVA, Feb. 15 -- WAVERLEY PHARMA INC. (4-1250 Waverley StreetWinnipeg, Manitoba R3T 6C6) filed a patent application (PCT/CA2025/051035) for "SUBSTITUTED (3-HYDROQUINAZOLIN-4-ONE) DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USE AS POTENT & SELECTIVE POLY [ADP RIBOSE] POLYMERASE 1(P ARP-1) INHIBITORS FOR THE TREATMENT OF CANCER" on Aug 05, 2025. With publication no. WO/2026/030819, the details related to the patent application was published on Feb 12, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): TWIBANIRE, Jean-d'amour K. (c/o WAVERLEY PHARMA INC.4-1250 Waverley StreetWinnipeg, Ma...